NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

东莨菪鹼经皮吸收制剂的全球市场

Transdermal Scopolamine

出版商 Global Industry Analysts, Inc. 商品编码 997608
出版日期 内容资讯 英文 103 Pages
商品交期: 最快1-2个工作天内
价格
东莨菪鹼经皮吸收制剂的全球市场 Transdermal Scopolamine
出版日期: 2021年04月01日内容资讯: 英文 103 Pages
简介

全球东莨菪鹼经皮吸收制剂的市场规模,预计在分析期间(2020年~2027年)将以5.3%的年复合成长率增长,从2020年的3亿6,870万美元,到2027年达到5亿2,850万美元。

本报告提供全球东莨菪鹼经皮吸收制剂市场的相关调查,提供市场占有率,Covid-19的影响,趋势和成长要素,各地区的市场分析,竞争情形,主要企业的简介等资讯。

调查对象企业范例

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

目录

I. 调查手法

II. 摘要整理

  • 市场概要
    • 影响者市场洞察
    • 全球市场的轨迹
    • Covid-19的影响与即将到来的全球景气衰退
  • 主要企业
  • 趋势与推动要素
  • 全球市场预测

III. 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 其他地区

IV. 竞争

  • 企业简介:41公司

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: MCP16073

Abstract:

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.

The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured) -

  • Alchem International
  • Alkaloids of Australia
  • ALZA Corporation
  • Baxter International Inc.
  • Caleb Pharmaceuticals Inc
  • Centroflora-Cms
  • Fine Chemicals Corporation
  • GlaxoSmithKline Plc
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Phytex Australia

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 4: USA Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 5: USA Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CANADA
    • TABLE 6: Canada Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 7: Canada Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • JAPAN
    • TABLE 8: Japan Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 9: Japan Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CHINA
    • TABLE 10: China Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 11: China Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • EUROPE
    • TABLE 12: Europe Current & Future Analysis for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 13: Europe Historic Review for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 14: Europe 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 15: France Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 16: France Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • GERMANY
    • TABLE 17: Germany Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Germany Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ITALY
    • TABLE 19: Italy Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Italy Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
    • TABLE 21: UK Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 22: UK Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
    • TABLE 23: Rest of Europe Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Rest of Europe Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
    • TABLE 25: Asia-Pacific Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Asia-Pacific Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF WORLD
    • TABLE 27: Rest of World Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Rest of World Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

IV. COMPETITION

  • Total Companies Profiled: 41